384 related articles for article (PubMed ID: 25115890)
1. A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis.
Palladini G; Hegenbart U; Milani P; Kimmich C; Foli A; Ho AD; Vidus Rosin M; Albertini R; Moratti R; Merlini G; Schönland S
Blood; 2014 Oct; 124(15):2325-32. PubMed ID: 25115890
[TBL] [Abstract][Full Text] [Related]
2. Renal risk and response in amyloidosis.
Dispenzieri A
Blood; 2014 Oct; 124(15):2315-6. PubMed ID: 25301329
[TBL] [Abstract][Full Text] [Related]
3. Light-chain amyloidosis with renal involvement: renal outcomes and validation of two renal staging systems in the Chinese population.
Zhu Z; Yue C; Sun Y; Li X; Li M
Amyloid; 2019 Dec; 26(4):186-191. PubMed ID: 31339366
[No Abstract] [Full Text] [Related]
4. Renal outcomes in patients with AL amyloidosis: Prognostic factors, renal response and the impact of therapy.
Kastritis E; Gavriatopoulou M; Roussou M; Migkou M; Fotiou D; Ziogas DC; Kanellias N; Eleutherakis-Papaiakovou E; Panagiotidis I; Giannouli S; Psimenou E; Marinaki S; Apostolou T; Gakiopoulou H; Tasidou A; Papassotiriou I; Terpos E; Dimopoulos MA
Am J Hematol; 2017 Jul; 92(7):632-639. PubMed ID: 28370245
[TBL] [Abstract][Full Text] [Related]
5. Long-term prognosis of AL and AA renal amyloidosis: a Japanese single-center experience.
Ozawa M; Komatsuda A; Ohtani H; Nara M; Sato R; Togashi M; Takahashi N; Wakui H
Clin Exp Nephrol; 2017 Apr; 21(2):212-227. PubMed ID: 27116248
[TBL] [Abstract][Full Text] [Related]
6. Prolonged renal survival in light chain amyloidosis: speed and magnitude of light chain reduction is the crucial factor.
Rezk T; Lachmann HJ; Fontana M; Sachchithanantham S; Mahmood S; Petrie A; Whelan CJ; Pinney JH; Foard D; Lane T; Youngstein T; Wechalekar AD; Bass P; Hawkins PN; Gillmore JD
Kidney Int; 2017 Dec; 92(6):1476-1483. PubMed ID: 28729034
[TBL] [Abstract][Full Text] [Related]
7. Prospective urinary albumin/creatinine ratio for diagnosis, staging, and organ response assessment in renal AL amyloidosis: results from a large cohort of patients.
Basset M; Milani P; Ferretti VV; Nuvolone M; Foli A; Benigna F; Nanci M; Bozzola M; Ripepi J; Sesta M; Russo F; Bosoni T; Klersy C; Albertini R; Merlini G; Palladini G
Clin Chem Lab Med; 2022 Feb; 60(3):386-393. PubMed ID: 35018751
[TBL] [Abstract][Full Text] [Related]
8. Growth differentiation factor-15 is a new biomarker for survival and renal outcomes in light chain amyloidosis.
Kastritis E; Papassotiriou I; Merlini G; Milani P; Terpos E; Basset M; Akalestos A; Russo F; Psimenou E; Apostolakou F; Roussou M; Gavriatopoulou M; Eleutherakis-Papaiakovou E; Fotiou D; Ziogas DC; Papadopoulou E; Pamboucas C; Dimopoulos MA; Palladini G
Blood; 2018 Apr; 131(14):1568-1575. PubMed ID: 29386197
[TBL] [Abstract][Full Text] [Related]
9. Cardiorenal AL amyloidosis: risk stratification and outcomes based upon cardiac and renal biomarkers.
Rezk T; Lachmann HJ; Fontana M; Naharro AM; Sachchithanantham S; Mahmood S; Petrie A; Whelan CJ; Pinney JH; Foard D; Lane T; Youngstein T; Wechalekar AD; Hawkins PN; Gillmore JD
Br J Haematol; 2019 Aug; 186(3):460-470. PubMed ID: 31124579
[TBL] [Abstract][Full Text] [Related]
10. The utility of repeat kidney biopsy in systemic immunoglobulin light chain amyloidosis.
Angel-Korman A; Jaberi A; Sanchorawala V; Havasi A
Amyloid; 2020 Mar; 27(1):17-24. PubMed ID: 31595786
[No Abstract] [Full Text] [Related]
11. The impact of dialysis on the survival of patients with immunoglobulin light chain (AL) amyloidosis undergoing autologous stem cell transplantation.
Leung N; Kumar SK; Glavey SV; Dispenzieri A; Lacy MQ; Buadi FK; Hayman SR; Dingli D; Kapoor P; Zeldenrust SR; Russell SJ; Lust JA; Hogan WJ; Rajkumar SV; Gastineau DA; Kourelis TV; Lin Y; Gonsalves WI; Go RS; Gertz MA
Nephrol Dial Transplant; 2016 Aug; 31(8):1284-9. PubMed ID: 26627634
[TBL] [Abstract][Full Text] [Related]
12. Severity of baseline proteinuria predicts renal response in immunoglobulin light chain-associated amyloidosis after autologous stem cell transplantation.
Leung N; Dispenzieri A; Lacy MQ; Kumar SK; Hayman SR; Fervenza FC; Cha SS; Gertz MA
Clin J Am Soc Nephrol; 2007 May; 2(3):440-4. PubMed ID: 17699449
[TBL] [Abstract][Full Text] [Related]
13. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes.
Palladini G; Dispenzieri A; Gertz MA; Kumar S; Wechalekar A; Hawkins PN; Schönland S; Hegenbart U; Comenzo R; Kastritis E; Dimopoulos MA; Jaccard A; Klersy C; Merlini G
J Clin Oncol; 2012 Dec; 30(36):4541-9. PubMed ID: 23091105
[TBL] [Abstract][Full Text] [Related]
14. Successful treatment of renal light chain (AL) amyloidosis with bortezomib and dexamethasone (VD).
Huang B; Li J; Xu X; Zheng D; Zhou Z; Liu J
Pathol Biol (Paris); 2015 Feb; 63(1):17-20. PubMed ID: 25455933
[TBL] [Abstract][Full Text] [Related]
15. European Collaborative Study Defining Clinical Profile Outcomes and Novel Prognostic Criteria in Monoclonal Immunoglobulin M-Related Light Chain Amyloidosis.
Sachchithanantham S; Roussel M; Palladini G; Klersy C; Mahmood S; Venner CP; Gibbs S; Gillmore J; Lachmann H; Hawkins PN; Jaccard A; Merlini G; Wechalekar AD
J Clin Oncol; 2016 Jun; 34(17):2037-45. PubMed ID: 27114592
[TBL] [Abstract][Full Text] [Related]
16. A phase II trial of lenalidomide, dexamethasone and cyclophosphamide for newly diagnosed patients with systemic immunoglobulin light chain amyloidosis.
Cibeira MT; Oriol A; Lahuerta JJ; Mateos MV; de la Rubia J; Hernández MT; Granell M; Fernández de Larrea C; San Miguel JF; Bladé J;
Br J Haematol; 2015 Sep; 170(6):804-13. PubMed ID: 25974382
[TBL] [Abstract][Full Text] [Related]
17. Clinical features of patients with immunoglobulin light chain amyloidosis (AL) with vascular-limited deposition in the kidney.
Eirin A; Irazabal MV; Gertz MA; Dispenzieri A; Lacy MQ; Kumar S; Sethi S; Nasr SH; Cornell LD; Fidler ME; Fervenza FC; Leung N
Nephrol Dial Transplant; 2012 Mar; 27(3):1097-101. PubMed ID: 22067518
[TBL] [Abstract][Full Text] [Related]
18. Bortezomib with dexamethasone as first-line treatment for AL amyloidosis with renal involvement.
Huang X; Wang Q; Chen W; Ren G; Liu Z
Amyloid; 2016; 23(1):51-7. PubMed ID: 26862817
[TBL] [Abstract][Full Text] [Related]
19. Trends in Survival and Renal Recovery in Patients with Multiple Myeloma or Light-Chain Amyloidosis on Chronic Dialysis.
Decourt A; Gondouin B; Delaroziere JC; Brunet P; Sallée M; Burtey S; Dussol B; Ivanov V; Costello R; Couchoud C; Jourde-Chiche N
Clin J Am Soc Nephrol; 2016 Mar; 11(3):431-41. PubMed ID: 26728585
[TBL] [Abstract][Full Text] [Related]
20. Renal response after high-dose melphalan and stem cell transplantation is a favorable marker in patients with primary systemic amyloidosis.
Leung N; Dispenzieri A; Fervenza FC; Lacy MQ; Villicana R; Cavalcante JL; Gertz MA
Am J Kidney Dis; 2005 Aug; 46(2):270-7. PubMed ID: 16112045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
